CD22 Antibody / CD22 molecule, 20ug

CD22, also known as Siglec-2 and B-cell receptor CD22, is a B cell-restricted transmembrane glycoprotein encoded by the CD22 gene that functions as a critical regulator of B cell receptor signaling and immune tolerance. CD22 Antibody for IHC / CD22 Immunohistochemistry Antibody (clone MSVA-022R) is optimized for high-resolution detection of CD22 in formalin-fixed, paraffin-embedded tissues, enabling precise visualization of B cell populations within intact tissue architecture. CD22 expression is tightly restricted to mature B lymphocytes, including follicular and mantle zone B cells, making it a highly specific marker for identifying B cell lineage in immunohistochemistry studies.<br><br>CD22 antibody, also referred to as Siglec-2 antibody or B-cell receptor CD22 antibody in the literature, is uniquely suited for tissue-based analysis where spatial context is essential. In immunohistochemistry, CD22 demonstrates a consistent membranous and cytoplasmic staining pattern that highlights B cell distribution within lymphoid organs such as lymph node, tonsil, and spleen. This staining pattern allows clear delineation of germinal centers and surrounding B cell zones, supporting detailed evaluation of lymphoid architecture in both normal and reactive tissues.<br><br>The strength of CD22 Antibody for IHC is particularly evident in tissue microarray analysis, where parallel staining across a wide range of normal tissues reinforces its lineage specificity. In tissue microarray panels, CD22 staining is consistently confined to lymphoid compartments, with strong signal observed in B cell-rich regions and minimal to absent staining in epithelial, stromal, and parenchymal tissues. This high contrast between positive and negative compartments enhances interpretability and makes CD22 a reliable marker for identifying lymphoid infiltrates within complex tissue environments.<br><br>In cancer tissue microarray studies, CD22 expression remains robust in B cell-derived malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and other non-Hodgkin lymphomas. Immunohistochemistry staining highlights neoplastic B cells with clear membranous and cytoplasmic localization, allowing distinction from surrounding non-neoplastic cells. Importantly, most non-B cell tumors lack CD22 expression, further supporting its use as a lineage-specific marker in diagnostic and research immunohistochemistry applications.<br><br>The recombinant rabbit monoclonal format of this CD22 antibody, clone MSVA-022R, supports consistent staining intensity and low background across tissue microarray platforms, where reproducibility is critical for comparative analysis. This consistency is particularly valuable in large-scale tissue microarray studies that require uniform performance across diverse tissue types and experimental conditions.<br><br>Due to its restricted expression profile, strong performance in FFPE tissues, and compatibility with tissue microarray workflows, CD22 remains an essential marker for immunohistochemistry-based investigation of B cell biology, tumor classification, and immune cell distribution. This CD22 antibody enables detailed tissue-level analysis, supporting studies of lymphoid organization, malignant B cell identification, and immune infiltration within normal and diseased tissues.<br><br>This antibody is part of the broader <a href=../cd22-antibody-b-cell-marker.html>CD22 antibody</a> collection for studying B cell markers, immune regulation, and hematologic malignancies.<br><br>This antibody is also part of a broader collection of <a href='/ihc-antibodies-tissue-microarray-validated.html'>IHC antibodies validated by tissue microarray analysis</a>, supporting consistent staining across normal and cancer tissues.

Specifications